Article
Oncology
Lijuan Li, Dan Yang, Yanmei Min, Anyan Liao, Jing Zhao, Leilei Jiang, Xin Dong, Wei Deng, Huiming Yu, Rong Yu, Jun Zhao, Anhui Shi
Summary: This study aimed to assess the safety and efficacy of chemoimmunotherapy combined with thoracic radiotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC). A total of 36 patients with ES-SCLC received this treatment modality at one hospital. The results showed that this treatment approach is safe and has good survival outcomes.
Review
Oncology
Bryan Oronsky, Nacer Abrouk, Scott Caroen, Michelle Lybeck, Xiaoning Guo, Xiaohui Wang, Zhongwen Yu, Tony Reid
Summary: For close to 40 years, small-cell lung cancer (SCLC) has been stagnant with no progress or effective treatments. However, between 2018 and 2021, several new drugs were approved, bringing hope to SCLC patients.
Article
Oncology
Yosuke Shionoya, Akito Hattori, Taro Hanada, Michihiro Fujino
Summary: This study describes a case of immune-related encephalitis in a patient with ES-SCLC, demonstrating the effectiveness of steroid therapy in treating durvalumab-induced encephalitis. The patient experienced neurological complications after durvalumab treatment, but showed significant improvement in symptoms after receiving steroid therapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Shuang Zhang, Ying Cheng
Summary: Small-cell lung cancer (SCLC) is a deadly type of lung cancer with limited treatment options. Recent studies have shown that adding immunotherapy to chemotherapy can improve the survival of patients with extensive-stage SCLC, establishing a new standard of first-line treatment. This article reviews the current status of first-line immunotherapy, strategies to enhance its efficacy, and the identification of potential predictive biomarkers for immunotherapy in SCLC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Luckson Mathieu, Sujay Shah, Lee Pai-Scherf, Erin Larkins, Jonathon Vallejo, Xiaoxue Li, Lisa Rodriguez, Pallavi Mishra-Kalyani, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Harpreet Singh
Summary: Atezolizumab and durvalumab, in combination with chemotherapy, have been approved by the FDA for first-line treatment of extensive stage small cell lung cancer, showing improved overall survival in clinical trials. These approvals mark a significant advancement in treatment options for small cell lung cancer patients.
Article
Oncology
Chun-Chia Chen, Kuan-Hua Tseng, Kuan-Lin Lai, Chi-Lu Chiang
Summary: Recently, immune checkpoint inhibitors (ICIs) have become the standard treatment option for lung cancer patients, including small cell lung cancer (SCLC). This case report highlights a patient with extensive-stage SCLC who developed neurological symptoms after receiving chemoimmunotherapy. The timely diagnosis and successful treatment of immune-related cerebellar ataxia led to significant improvement in neurological symptoms and prolonged progression-free survival.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Ryan D. Gentzler, Liza C. Villaruz, John C. Rhee, Bethany Horton, Joseph Mock, Michael Hanley, Kyeongmin Kim, Michelle A. Rudek, Mitch A. Phelps, Michael A. Carducci, Richard Piekarz, Kwon-Sik Park, Timothy N. Bullock, Charles M. Rudin
Summary: This study evaluated the safety of combining the HDAC inhibitor entinostat with standard of care chemotherapy and immunotherapy in patients with small cell lung cancer. The results showed that the addition of entinostat resulted in early onset and severe neutropenia and thrombocytopenia, indicating that further exploration of this combination therapy is not recommended.
Article
Oncology
L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M. J. Hochmair, M. Ozguroglu, J. H. Ji, M. C. Garassino, O. Voitko, A. Poltoratskiy, E. Musso, L. Havel, I Bondarenko, G. Losonczy, N. Conev, H. Mann, T. B. Dalvi, H. Jiang, J. W. Goldman
Summary: In extensive-stage small-cell lung cancer (ES-SCLC), durvalumab plus EP continues to improve overall survival (OS), while durvalumab plus tremelimumab plus EP shows numerical improvement but does not reach statistical significance.
Article
Oncology
Emanuele Vita, Alessio Stefani, Geny Piro, Luca Mastrantoni, Marco Cintoni, Giuseppe Cicchetti, Ileana Sparagna, Federico Monaca, Guido Horn, Jacopo Russo, Diletta Barone, Mariantonietta Di Salvatore, Rocco Trisolini, Filippo Lococo, Ciro Mazzarella, Alessandra Cancellieri, Carmine Carbone, Anna Rita Larici, Maria Cristina Mele, Sara Pilotto, Michele Milella, Giampaolo Tortora, Emilio Bria
Summary: Leptin may play a crucial role in the effectiveness of immunotherapy in lung adenocarcinoma, and is associated with metabolic immune dysfunctions.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Immunology
Bi-Cheng Wang, Chen Fu, Guo-He Lin
Summary: By analyzing clinical trial data, we found that adebrelimab has better survival data compared to durvalumab and atezolizumab in the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Arani Sathiyapalan, Michela Febbraro, Gregory R. Pond, Peter M. Ellis
Summary: Combining immune checkpoint inhibitors (ICI) with chemotherapy for untreated small cell lung cancer (SCLC) patients can significantly improve survival, reduce the risk of disease progression, and have minimal increase in toxicity.
Article
Oncology
Martin Reck, Tony S. K. Mok, Aaron Mansfield, Richard De Boer, Gyorgy Losonczy, Shunichi Sugawara, Rafal Dziadziuszko, Maciej Krzakowski, Alexey Smolin, Maximilian Hochmair, Marina Chiara Garassino, Gilberto de Castro Junior, Helge Bischoff, Sivuonthanh Lam, Andres Cardona, Stefanie Morris, Stephen Liu
Summary: The IMpower133 study demonstrated that atezolizumab in combination with carboplatin and etoposide improved overall survival and progression-free survival in first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Further analysis revealed that the benefits of atezolizumab maintenance therapy persisted after adjusting for baseline characteristics, and the safety profile was similar to the placebo group.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Review
Cell Biology
Yan Lin, Wei Jiang, Cui-Yun Su, Xin-Bin Pan
Summary: This study assessed the impact of liver metastases on the survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC) patients. The results showed that immunotherapy plus chemotherapy had better disease control and survival outcomes in patients without liver metastases, while it did not have significant benefits in patients with liver metastases.
Article
Oncology
Jie Zhao, Yayi He, Xue Yang, Panwen Tian, Liang Zeng, Kun Huang, Jing Zhao, Jiaqi Zhou, Yin Zhu, Qiyuan Wang, Mailin Chen, Wen Li, Yi Gao, Yongchang Zhang, Yang Xia
Summary: This retrospective study investigated the treatment outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC) receiving chemoimmunotherapy. The study found that a clinical and radiomics model could predict the treatment outcomes in these patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
Jun Ni, Xiaoyan Si, Hanping Wang, Xiaotong Zhang, Li Zhang
Summary: This study evaluates the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer (ES-SCLC) patients. The results show that IP/IC plus camrelizumab group has a median PFS of 10.25 months, and the objective response rate is 89.6%.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Jacques Cadranel, Stephen V. Liu, Michael Duruisseaux, Eva Branden, Yasushi Goto, Benjamin A. Weinberg, Christoph Heining, Richard F. Schlenk, Parneet Cheema, Martin R. Jones, Alexander Drilon, Domenico Trombetta, Lucia Anna Muscarella, Khaled Tolba, Valerie Gounant, Agnieszka Cseh, Flavio Solca, Janessa J. Laskin, Daniel J. Renouf
Summary: Neuregulin 1 (NRG1) fusions, rare oncogenic drivers in multiple tumor types, can be effectively treated with afatinib, a pan-ErbB family inhibitor. This report summarizes six cases of metastatic NRG1 fusion-driven tumors treated with afatinib, with several patients showing a prolonged response of >18 months.
Article
Oncology
Adriana Estrada-Bernal, Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull, Jeff B. Smaill, Adam V. Patterson, Chul Kim, Stephen V. Liu, Robert C. Doebele
Summary: Tarloxotinib, a prodrug that utilizes tumor hypoxia to generate a potent pan-HER tyrosine kinase inhibitor, demonstrated selective delivery to tumor cells and effective inhibition of EGFR exon 20, ERBB2 mutations, and NRG1 fusions in cancer models. The concentrated presence of tarloxotinib-E in tumor tissues led to tumor regression and growth inhibition in mouse xenografts, with promising clinical responses observed in patients with relevant mutations.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Stephen Liu, Martin Reck, Aaron S. Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier De Castro Carpeno, Raffaele Califano, Makoto Nishio, Francisco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong-Seok Lee, Sivuonthanh Lam, Mark McCleland, Yu Deng, See Phan, Leora Horn
Summary: IMpower133 trial showed that adding atezolizumab to CP/ET for first-line treatment of ES-SCLC significantly improved patients' overall survival. Atezolizumab demonstrated potential efficacy in treating ES-SCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Rafal Dziadziuszko, Matthew G. Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C. Doebele, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Anna F. Farago, Chia-Chi Lin, Christos S. Karapetis, Yu-Chung Li, Bann-mo Day, David Chen, Timothy R. Wilson, Fabrice Barlesi
Summary: Entrectinib continues to show a high level of clinical benefit for patients with ROS1 fusion-positive NSCLC, including those with central nervous system metastases.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Elizabeth Dudnik, Samuel Kareff, Mor Moskovitz, Chul Kim, Stephen Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar
Summary: This study of 125 patients suggests a positive impact of ICI on overall survival in aLCNEC, despite the limitations of retrospective design and small sample size.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Diego Cortinovis, Paolo Bidoli, Stefania Canova, Francesca Colonese, Maria Gemelli, Maria Luisa Lavitrano, Giuseppe Luigi Banna, Stephen V. Liu, Alessandro Morabito
Summary: Small cell lung cancer is a deadly subtype of lung cancer with fast doubling time and early metastasis. Traditional chemotherapy regimens have shown high response rates, but early chemoresistance leads to poor prognosis in advanced cases. Only a few patients with limited disease can be cured through chemo-radiotherapy, and the development of novel chemotherapy agents is eagerly awaited due to disappointing survival rates in advanced stages.
Article
Oncology
Stephen V. Liu
Summary: NRG1 fusions are rare oncogenic drivers found at low frequencies across multiple tumor types, with an estimated incidence of 0.2% in lung cancer. Despite challenges in detection due to large intronic regions, NRG1 fusions represent potential therapeutic targets. Early evidence of efficacy has been shown for agents targeting the ErbB signaling pathway, with limited supporting data mostly from case reports and small series, but prospective trials are ongoing. The evolving understanding suggests that NRG1 will be clinically relevant in the future.
Review
Oncology
Joshua E. Reuss, Laura Gosa, Stephen Liu
Summary: ADCs combine the specificity of a monoclonal antibody with the cytotoxic effects of chemotherapy to facilitate targeted delivery of cytotoxic payloads to cancer cells. ADCs show promise in lung cancer treatment, with future applications looking increasingly relevant.
CLINICAL LUNG CANCER
(2021)
Article
Oncology
George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Summary: This study provides additional evidence on the safety and efficacy of Entrectinib in treating NTRK fusion-positive solid tumors, with prolonged follow-up and an increased number of patients.
CLINICAL CANCER RESEARCH
(2022)
Editorial Material
Oncology
Charu Aggarwal, Stephen V. Liu
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Stephen V. Liu, Ivy B. Elkins, Jill Feldman, Sarah B. Goldberg
Summary: This podcast discusses the importance of biomarker testing for patients with EGFR-mutated non-small cell lung cancer, including the definition of biomarkers, the process of obtaining biomarker testing, and the significance of waiting for biomarker results before determining treatment. The panel also explores patient perspectives on biopsy and biomarker testing, as well as how healthcare professionals can guide new patients through this process.
ONCOLOGY AND THERAPY
(2023)
Article
Oncology
Stephen Liu, Tony S. K. Mok, Barzin Y. Nabet, Aaron S. Mansfield, Richard De Boer, Gyorgy Losonczy, Shunichi Sugawara, Rafal Dziadziuszko, Maciej Krzakowski, Alexey Smolin, Maximilian J. Hochmair, Marina C. Garassino, Carl M. Gay, John Heymach, Lauren A. Byers, Sivuonthanh Lam, Andres Cardona, Stefanie Morris, Leah Adler, David S. Shames, Martin Reck
Summary: In the Phase I/III IMpower133 study, atezolizumab in combination with carboplatin and etoposide demonstrated improved overall survival and progression-free survival for patients with extensive-stage small cell lung cancer. The study also revealed associations between long-term survival and patient and disease characteristics, as well as differential gene expression and SCLC transcriptional subtypes.
Article
Oncology
Xiuning Le, Lingzhi Hong, Chuck Hensel, Rongrong Chen, Haley Kemp, Niamh Coleman, Christine A. Ciunci, Stephen Liu, Marcelo Negrao, Jennifer Yen, Xuefeng Xia, Juergen Scheuenpflug, Christopher Stroh, Dilafruz Juraeva, Anne Tsao, David Hong, Victoria Raymond, Paul Paik, Jianjun Zhang, John Heymach
Summary: METex14 mutations frequently co-occur with other potential driver oncogenes with differing patterns of clonal dominance observed among the drivers. This cellular context can provide insights into whether METex14 is acting as a primary oncogenic driver or resistance mechanism and help guide treatment choices.
JCO PRECISION ONCOLOGY
(2021)
Review
Oncology
Saira Farid, Stephen V. Liu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2020)
Review
Respiratory System
Michael T. Serzan, Saira Farid, Stephen Liu
JOURNAL OF THORACIC DISEASE
(2020)